webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

MC-Gly-Gly-D-Phe

  CAS No.:   Cat No.: BADC-01893 4.5  

MC-Gly-Gly-D-Phe is a dipeptide-based ADC linker intermediate designed for enzymatic cleavage and controlled payload release in antibody-drug conjugates, enhancing therapeutic index and specificity. Keywords: ADC linker, peptide linker, cleavable linker, controlled release, antibody-drug conjugates.

MC-Gly-Gly-D-Phe

Structure of

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Linker
Molecular Formula
C23H28N4O7
Molecular Weight
472.49

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
IUPAC Name
(2R)-2-[[2-[[2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]acetyl]amino]acetyl]amino]-3-phenylpropanoic acid
Canonical SMILES
C1=CC=C(C=C1)CC(C(=O)O)NC(=O)CNC(=O)CNC(=O)CCCCCN2C(=O)C=CC2=O
InChI
InChI=1S/C23H28N4O7/c28-18(9-5-2-6-12-27-21(31)10-11-22(27)32)24-14-19(29)25-15-20(30)26-17(23(33)34)13-16-7-3-1-4-8-16/h1,3-4,7-8,10-11,17H,2,5-6,9,12-15H2,(H,24,28)(H,25,29)(H,26,30)(H,33,34)/t17-/m1/s1
InChIKey
NFVPAFLSJIPUCL-QGZVFWFLSA-N

MC-Gly-Gly-D-Phe, a synthetic peptide derivative, is widely used in the design and synthesis of targeted drug delivery systems, particularly in the development of antibody-drug conjugates (ADCs). The molecule’s structure incorporates a maleimide (MC) functional group, enabling selective conjugation with thiol groups on antibodies, forming stable thioether linkages. This feature ensures precise attachment of cytotoxic payloads to antibodies, enhancing the therapeutic index and reducing systemic toxicity in cancer treatments.

The Gly-Gly-D-Phe sequence in MC-Gly-Gly-D-Phe serves as a cleavable linker in drug delivery applications. This peptide sequence is highly sensitive to enzymatic cleavage in the tumor microenvironment, where proteases such as cathepsins are overexpressed. Upon cleavage, the cytotoxic payload is released specifically at the target site, minimizing off-target effects and maximizing therapeutic efficacy. This selective activation mechanism makes MC-Gly-Gly-D-Phe a critical component in targeted therapies for oncology.

MC-Gly-Gly-D-Phe is also employed in the development of peptide-based prodrugs. The compound's cleavable linker properties allow for the design of prodrugs that remain inactive during systemic circulation and are activated only in the presence of specific enzymes. This controlled activation reduces side effects and enhances the pharmacokinetic profile of the therapeutic agents, making it a valuable tool in precision medicine.

In addition to drug delivery, MC-Gly-Gly-D-Phe is utilized in biochemical research to study enzymatic activity and protease specificity. By incorporating this peptide sequence into fluorogenic or chromogenic substrates, researchers can monitor protease activity in real-time. This application is vital in understanding disease mechanisms and developing diagnostic assays for conditions characterized by aberrant protease activity, such as cancer and inflammatory diseases.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Linker Development Enzyme Cleavable Linker Cathepsin B Cleavable Linker/Peptide Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker Sulfatase Cleavable Linker Chemically Cleavable Linker Non-Cleavable Linker Services Acid Cleavable Linker/Hydrazone Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Linkers - A Crucial Factor in Antibody–Drug Conjugates In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress New Structural Insights Solve Instability Issues of Maleimide Linkers in ADCs PEG Linkers in Antibody-Drug Conjugates Peptide Linkers in Antibody-Drug Conjugates Disulfide Linkers in Antibody-Drug Conjugates Biotinylation Reagents in Antibody-Drug Conjugates Maleimide Linkers in Antibody-Drug Conjugates Current ADC Linker Chemistry SPDB Linkers in Antibody-Drug Conjugates

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: 1-BOC-Azetidine-3-carboxylic acid methyl ester | Mc-Gly-Gly-Phe-Gly-PAB-OH TFA | H-L-Lys(N3-Gly)-OH hydrochloride | trans-Cyclooctene-PEG(3)-maleimide | H-L-Lys(4-N3-Z)-OH HCl | MC-Gly-Gly-D-Phe
Send Inquiry
Verification code
Inquiry Basket